O R McIntyre

TL;DR: The concept of a dose-response effect for cytarabine in patients with AML who are 60 years of age or younger is supported and the results with the high-dose schedule in this age group are comparable to those reported in similar patients who have undergone allogeneic bone marrow transplantation during a first remission.

TL;DR: In a randomized study of acute myelocytic leukemia (AML), 352 patients of all ages were treated for remission induction by one of the four regimens: 7 days of cytosine arabinoside (ara-C) by continuous intravenous (i.v.) infusion or bolus injection every 12 hr, together with daunorubicin (DNR) by rapid i.v. injection on days 1, 2, 3; or 5 days of ara-C by infusion and DNR for 2 days only as discussed by the authors.

TL;DR: Results confirm earlier reports of antigenic heterogeneity in AML, and indicate that immunologically defined subgroups of AML patients which are of potential clinical significance can be identified.

TL;DR: This trial does not support the superiority of A200 over A100 in the treatment of AML, but Stratification of data by age and PS suggested that A200 may improve survival in patients less than 60 years with a good PS 0.

TL;DR: A 60-year-old man with signs of anemia, thrombocytopenia and hyperviscosity was found to have multiple myeloma, and the abnormal serum globulin component was identified as IgE lambda protein, which when tested with antiserum to normal human IgE, gave a band of identity with serum from the only previously described case of IgEMyeloma.